Medicare reimbursed transplant centers $2.8 million for a sample that included 43 organs used in transplants outside Medicare and 12 organs that were never transplanted, federal auditors found. The payments flowed from guidance that conflicted with the statute limiting which organ-acquisition costs Medicare can cover. The audit does not allege that hospitals fabricated the organs; it identifies a reimbursement rule that counted costs too broadly.
The Sample Contained 55 Organs Outside the Statutory Limit
The HHS Office of Inspector General examined 180 organs that transplant centers had reported as “Medicare usable.” Within that sample, Medicare reimbursed $2.8 million for 43 organs used in transplants that were not Medicare-covered and 12 organs never transplanted at all. Auditors concluded that federal statutory requirements did not permit Medicare reimbursement for the acquisition costs of those 55 organs.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
Organ Acquisition Uses Cost-Based Reimbursement
Medicare does not treat organ acquisition like a conventional item on a hospital bill. Certified transplant centers report allowable acquisition costs, and Medicare reimburses its share on a cost basis. In 2023, the program reimbursed more than $3 billion associated with roughly 39,000 organs. Federal law limits that support to organs used in Medicare-covered transplants, but CMS guidance assumed that organs furnished to another procurement organization or transplant center would ultimately serve a Medicare transplant.
The Assumption Failed When the Organ Took Another Path
An organ transferred between institutions may eventually go to a patient whose transplant is not covered by Medicare, or it may not be transplanted. The guidance treated the transfer itself as enough to keep the organ in the Medicare-usable calculation. OIG found that reality did not always match that assumption. The result was not a dispute over whether organ procurement has costs; it was a question of which payer should bear them after the final use became known.
Five More Organs Lacked Supporting Documents
Auditors separately found that two transplant centers could not provide documentation for five organs reported as Medicare usable. Those payments totaled $154,210. OIG recommended that CMS direct its contractors to recover that amount. CMS agreed with the recovery recommendation. This finding is narrower than the guidance conflict because it concerns missing evidence in particular cost reports rather than the policy used to allocate properly documented costs.
The Larger Estimate Reached Nearly $380 Million
Using the sample, OIG estimated that Medicare paid about $380 million over six years for organ-acquisition costs outside Medicare-covered transplants. It recommended revising CMS guidance to match federal law. CMS did not specifically concur or disagree with that policy recommendation, and the public tracker lists it as open and unimplemented. The $2.8 million in the headline is the observed sample amount; the much larger number is a statistical estimate across the audit period and should not be confused with a directly reviewed set of payments.
The Audit Does Not Challenge Organ-Sharing Itself
Transplant centers and organ-procurement organizations must move organs across institutions to find suitable recipients quickly. OIG did not recommend ending that sharing. Its concern was financial attribution after the organ’s final use became known. Medicare can support acquisition costs for a Medicare-covered transplant, but the statute does not make the program the default payer whenever a Medicare-certified center handled the organ somewhere along the chain. Revised guidance could preserve clinical sharing while requiring cost reports to follow the eventual transplant and payer. That distinction protects both the transplant system and the legal boundary on Medicare spending.
CMS agreed that contractors should recover the $154,210 lacking documentation but did not specifically concur or disagree with the broader guidance recommendation. Both recommendations remain open in the public tracker. The next step is administrative correction, not a new benefit restriction imposed on transplant patients.
The six-year estimate of $379,895,793 represents what auditors calculated could have been saved if the statutory definition had governed the sampled universe. It is not a bill sent to individual transplant centers. CMS must decide how to revise instructions and apply any recovery rules within administrative and legal limits.
Future cost reports will determine whether the guidance change prevents similar allocations without disrupting the clinical speed required for organ placement.
The audit leaves patient coverage unchanged. Implementation will determine the audit’s practical effect.
Household Medicare Help Beyond Hospital Accounting
The organ-cost audit concerns payments between Medicare and transplant centers. Separately, Medicare Savings Programs, Extra Help and state drug assistance can reduce household costs but require their own applications.
The Benefits Checklist covers 11 programs in 69 pages, with 2026 income limits and the 50-state phone directory.
Review the household-assistance guide in The Benefits Checklist.
AI tools assisted in researching and drafting this article, which was reviewed prior to publication.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
